(Q39614541)

13 September 2017

A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis (English)

1 reference

13 September 2017

1 reference

Yardley V

1

1 reference

PubMed ID

10755238

13 September 2017

Croft SL

series ordinal

2

1 reference

PubMed ID

10755238

13 September 2017

language of work or name

1 reference

1 February 2000

1 reference

International Journal of Antimicrobial Agents

13 September 2017

1 reference

13 September 2017

13

1 reference

13 September 2017

4

1 reference

13 September 2017

243-248

1 reference

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Some compounds active against experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

The water and ionic permeability induced by polyene antibiotics across plasma membrane vesicles from Leishmania sp.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Mechanism of action of amphotericin B on Leishmania donovani promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Physicochemical cell damage in relation to lethal amphotericin B action

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Overview of liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Engineering liposomes for drug delivery: progress and problems

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Liposomes in the treatment of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Lipid formulations of amphotericin B: recent progress and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

The treatment of American (mucocutaneous) leishmaniasis with amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Diversity of lipid-based polyene formulations and their behavior in biological systems

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Rapid turnover of low density lipoprotein receptor in human monocytic THP-1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Release of amphotericin B from delivery systems and its action against fungal and mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Phagocyte uptake and transport of azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900133-8

7 January 2021

10.1016/S0924-8579(99)00133-8

Identifiers

DOI

1 reference

13 September 2017

1 reference

PubMed ID

10755238